An age- and mutation status-based scoring system accurately predicted survival in people with primary myelofibrosis in an analysis involving 344 individuals.

All participants had primary myelofibrosis, and were screened for the presence of Janus kinase 2, calreticulin, and myeloproliferative leukemia mutations. Among the results:

• Janus kinase 2 V617F was detected in two-thirds of patients; calreticulin mutation in 12%, and myeloproliferative leukemia mutation in 5%.
• 17% were triple-negative.
• Patients with a favorable mutation status (high Janus kinase 2V617F allele burden/ myeloproliferative leukemia/calreticulin mutation) and age ≤65 years survived a median of 126 months.
• Patients with 1 risk factor (low Janus kinase 2V617F allele burden/triple-negative or age >65 years) had an intermediate survival duration.
• Patients >65 years with an adverse mutation status (low Janus kinase 2V617F allele burden or triple-negative) had a median survival of 35 months.